Immunology

Westlake University Establishes School of Medicine

Retrieved on: 
Thursday, December 7, 2023
Hospital, Immunology, Metabolism, Immune system, Microbiology, Infection, Research, Vaccine, Trustee, Science, Tsinghua University, Inflammation, Westlake University, University, Public, MD Anderson Cancer Center, Face, Physiology, Medicine, Autoimmunity

Hangzhou, China, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Recently, the Board of Trustees of Westlake University decided to establish the Westlake University School of Medicine and appoint Professor Chen Dong, an academician of the Chinese Academy of Sciences and renowned immunologist, to act as the first dean of the school.

Key Points: 
  • Hangzhou, China, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Recently, the Board of Trustees of Westlake University decided to establish the Westlake University School of Medicine and appoint Professor Chen Dong, an academician of the Chinese Academy of Sciences and renowned immunologist, to act as the first dean of the school.
  • Westlake University President Yigong Shi said with the establishment of a new medical school, "we will work hard to build a new system of Westlake medical education and actively explore new ways to build a research-oriented medical school and contribute the strength of Westlake to the development of medicine in China and the world."
  • On November 6, Westlake University and the Hangzhou Municipal Health Commission signed a cooperation agreement to jointly develop the Hangzhou First People's Hospital Affiliated to the Westlake University School of Medicine.
  • He was Dean of Tsinghua University School of Medicine and Director at the Institute for Immunology at Tsinghua University, and also was Professor at Shanghai Jiao Tong University School of Medicine and Director for the Shanghai Immune Therapy Institute.

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Retrieved on: 
Thursday, November 30, 2023
Viremia, Infection, Immunology, Survival, Biotechnology, NIAID, Primate, Virus, Vaccination, Weight loss, Vaccine, Disease, UTMB, Congress, Human, SUDV, GeoVax, University, Death, Associate professor, EBOV, MARV, Cancer, Immunization, MVA

ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of data from recent preclinical studies of its vaccine candidates against Marburg virus and Sudan virus.

Key Points: 
  • The data were presented during the World Vaccine Congress, West Coast conference, being held in Santa Clara, CA from November 27-30, 2023.
  • Mark Newman, Ph.D., GeoVax Chief Scientific Officer, commented, “We are highly encouraged by the results of these studies of our MARV vaccine candidate.
  • The vaccine induced immune responses were characterized by MARV-specific binding and neutralizing antibodies as well as other effector functions like antibody-dependent phagocytosis.
  • The Angola strain is the most virulent strain of MARV characterized by a fatality rate of up to 90% in humans.

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Retrieved on: 
Monday, November 27, 2023
Christian democracy, Family, PDC, Antigen, B cell, Immunology, BDCA2, IND, Autoimmunity, Research, Plasma cell, SLE, Inflammation, Half-life, CD122, SAN, Lupus, GMP, CNTA, Monocyte, Patient, Antigen presentation, Therapy, Vaccine

Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.

Key Points: 
  • Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
  • Under the terms of the agreement, Anaptys will receive from Centessa Pharmaceuticals an exclusive, global license for ANB101.
  • Anaptys will also receive the same rights to ANB102, an extended half-life BDCA2 modulator with the potential to enable quarterly or less frequent dosing.
  • Centessa is eligible to receive an additional development milestone payment and low single-digit royalties on global net sales.

Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients

Retrieved on: 
Thursday, December 21, 2023
Long COVID, Long, Urinary tract infection, Immunology, University of Manchester, Immune system, Research, Trial of the century, University, Viral, Respiratory disease, Observational study, Immunity, Inflammation, IVD, Patient, Diagnosis, Vaccine

This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.

Key Points: 
  • This collaboration aims to apply the ViraxImmune IVD platform to broaden the understanding of T-Cell immune response in COVID patients in the ImRESP (Immunology of Respiratory Conditions) study.
  • Furthermore, within the ImRESP clinical study, the T-cell assay will be assessed in a distinct cohort of patients experiencing Long COVID symptoms.
  • This collaboration underscores Virax Biolabs' commitment to advancing diagnostic capabilities and understanding immune responses, particularly in post-viral syndromes and conditions associated with chronic inflammation.
  • The collaboration with the University of Manchester represents a significant step toward developing innovative solutions for diagnosing and managing post-viral syndromes.

McGovern Allergy & Asthma Clinic Is Proud To Announce The Sergio Lopez Food Allergy Awareness Act Passes in Texas

Retrieved on: 
Tuesday, December 19, 2023
Risk, Food, Legislation, Education, Allergy, Immunology, Food allergy, Optimism, Committee, Patient, Safety, DSHS, House

HOUSTON, Dec. 19, 2023 /PRNewswire-PRWeb/ -- A triumphant moment for the food allergy community unfolded on September 1st, 2023, as the Sergio Lopez Food Allergy Awareness Act, signed by Governor Abbot, officially took effect. This monumental legislation, a result of collaborative efforts involving several Texas Allergists, A testimony from McGovern Allergy and Asthma Clinic Board-Certified Allergists and Immunologist Dr. Serge de Golovine, Committee members from GHAAIS and TAAIS, as well as the dedicated lobbying team of Eric Woomer and Gertie Wilson, mandates the prominent display of standardized posters in all food service establishments, provided by the Department of State Health Services (DSHS).

Key Points: 
  • Governor Abbot signs The Sergio Lopez Food Allergy Awareness Act Passes in Texas; The Landmark Legislation Ensures Comprehensive Food Allergen Information in Restaurants Statewide
    HOUSTON, Dec. 19, 2023 /PRNewswire-PRWeb/ -- A triumphant moment for the food allergy community unfolded on September 1st, 2023, as the Sergio Lopez Food Allergy Awareness Act, signed by Governor Abbot, officially took effect.
  • In May, the bill successfully passed as the Sergio Lopez Food Allergy Awareness Act (SB 812), ushering in a new era of safety and awareness in the food service industry.
  • "At McGovern Allergy & Asthma Clinic, our team is dedicated to providing patients with comprehensive food allergy care and education.
  • For additional details about SB 812 and the Sergio Lopez Food Allergy Awareness Act, interested parties can refer to the official Texas legislative website.

New Series with Harvesting Happiness and Mental Immunity Project Explores Information Warfare, AI, Reality Testing and the Decline of Critical Thinking in Society

Retrieved on: 
Tuesday, December 19, 2023
Quality of life, Science, MIP, Epidemic, Culture, Immunology, Health, AI, LOS, KBUU-LP, Mind, Radio, HH, Carnegie Mellon University

LOS ANGELES, Dec. 19, 2023 /PRNewswire/ -- Andy Norman, Pittsburg researcher and professor at Carnegie Mellon University, author of Mental Immunity, and founder of the Mental Immunity Project (MIP) and its research arm The Cognitive Immunology Research Collaborative (CIRCE), joins Lisa Cypers Kamen, applied positive psychology expert, online talk-radio pioneer and host of syndicated podcast and terrestrial radio show Harvesting Happiness (HH), now in its 13th year of broadcasting consciously prepared brain food. Together, they embark on an 18-part series exploring the emerging science of cognitive immunology to defend against fear mongering and other negative contagions that stem from misinformation, disinformation, and infectious mindbugs undermining common sense and critical thinking that affect personal and collective well-being.

Key Points: 
  • "The series aims to empower truth-seekers and truth-tellers through rational dialogue, tackling media literacy and AI's impact on diminishing critical thinking and discernment in society.
  • The Mental Immunity Project and Harvesting Happiness enhance quality of life and productivity by building mental resilience, media intelligence, and critical thinking against misinformation.
  • Learn more about CIRCE , the Mental Immunity Project and Harvesting Happiness .
  • Please contact [email protected] for more information on the series or to book interviews with the collaborators.

Jeremy Caldwell, Ph.D., Accomplished Biopharma Executive, Company Creator and R&D Leader, Joins Red Tree Venture Capital as Partner

Retrieved on: 
Thursday, November 16, 2023
Initial public offering, Research, Red tree vole, Third Rock Ventures, Therapy, Versant, Merck & Co., Takeda, Scripps Research, Hotbed, Biotechnology, History, Genomics, Piz Sardona, Neurology, Immunology, Health, GNF, ARCH Venture Partners, Novartis, IPO, Drug discovery, San Francisco Bay Area, University, R, Icahn Genomics Institute, News, Big Pharma, RNA, UCSD, Fine chemical, Pharmaceutical industry, Inception, Cargo, Sirna

SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Red Tree Venture Capital (“Red Tree”), a West Coast-centric, early stage-biased life science venture capital firm, today announced that Jeremy Caldwell, Ph.D., a widely respected biopharmaceutical executive and research and development leader, whose accomplishments span from the creation of innovative drug development companies to driving the discovery, development and translation of novel therapies, has joined the firm as a partner. Dr. Caldwell brings Red Tree a range of deep industry expertise built throughout a career involving roles as a member of both industry and the venture community. In alignment with the firm’s West Coast focus, he has forged deep ties within the San Diego and San Francisco Bay Area biotechnology communities.

Key Points: 
  • Dr. Caldwell brings Red Tree a range of deep industry expertise built throughout a career involving roles as a member of both industry and the venture community.
  • Based in San Diego, Dr. Caldwell’s addition to Red Tree illustrates the firm’s increased emphasis on targeting company creation and investment opportunities emanating from the greater San Diego area.
  • “Jeremy has led an accomplished career in the biopharmaceutical space, achieving impressive successes from the perspectives of executive, R&D leader, and company builder.
  • He currently serves as a member of the board of Red Tree portfolio companies Sardona Therapeutics and Biograph 55.

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 15, 2023
Research, Therapy, Interim, Natural killer T cell, Insurance, Patient, Idiopathic pulmonary fibrosis, IPF, Abuse, SLE, Idiopathic disease, Conference, Lupus nephritis, Injury, Aardvark, NKT, GRI, Doctor of Philosophy, Inflammation, Fibrosis, Rare-earth element, Pharmaceutical industry, Vaccine, Immunology, Frontiers

LA JOLLA, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported its financial results for the quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Importantly, we believe 2024 will be the year of data for GRI Bio,” commented Marc Hertz, PhD, Chief Executive Officer of GRI Bio.
  • GRI Bio’s lead program, GRI-0621, is a small molecule RAR-βɣ dual agonist that inhibits the activity of human type 1 iNKT cells.
  • Research and development expenses were $2.2 million and $0.2 million for the nine months ended September 30, 2023 and 2022, respectively.
  • As of September 30, 2023, the Company had cash and cash equivalents of approximately $3.5 million.

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, November 14, 2023
CTL, AIM, Safety, NYSE, Senior, Breast cancer, Celecoxib, Roswell Park, Rintatolimod, Paper, Patient, TLR3, Journal, Immunology, CKM, Pembrolizumab, AIM ImmunoTech, Science of team science, Immunotherapy, Doctor of Philosophy, Manuscript, Pharmaceutical industry, Management, Cancer, MD

OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.

Key Points: 
  • OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate Ampligen® (also known as rintatolimod), interferon α-2b and celecoxib, followed by pembrolizumab.
  • The data were published in a manuscript titled, “ Systemic Infusion of TLR3-Ligand and IFNα in Breast Cancer Patients Reprograms Local Tumor Microenvironment for Selective CTL Influx ,” in The Journal for ImmunoTherapy of Cancer.
  • The pilot study evaluated the safety of systemic CKM composed of intravenous rintatolimod (Ampligen; selective TLR3 ligand), interferon α-2b and celecoxib, and the combination’s ability to promote local CTL influx to mTNBC lesions.
  • For more information about the study, please visit ClinicalTrials.gov: NCT03599453 .

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Tuesday, November 14, 2023
CNS, DSM-IV codes, DNA, Conditional sentence, Janssen Pharmaceuticals, Subthalamic nucleus, Patient, Research, ESGCT, FTD, Capsid, Quality control, Congress, I&I, Safety, Treatment, IND, Immunology, Inherited disorders of trafficking, ROFN, Evercore, Genome, STN, Central nervous system, Martin Lipton, Frontotemporal dementia, Xerostomia, Johnson & Johnson, MIA, GMP, Gene, BLA, Commercial, Insurance, Parotid gland, ALS, Parkinson's disease, Clinical trial, Obesity, QC, File, CGMP, RIX, Pharmaceutical industry, Vaccine, Cryptocurrency, Birth control, Sanofi, Janssen, Inflammation

Bota-vec for the Treatment of XLRP:

Key Points: 
  • Bota-vec for the Treatment of XLRP:
    Enrollment completed in second quarter 2023 in the pivotal Phase 3 LUMEOS clinical trial in collaboration with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.
  • In September 2023, the IND for bota-vec for the treatment of XLRP was transferred from MeiraGTx to Janssen.
  • Results from AQUAx Phase 1 open-label, dose-escalation study of gene therapy with AAV2-hAQP1 as a treatment for RIX and parotid gland hypofunction presented at ESGCT 2023 Annual Congress on October 26, 2023.
  • License revenue was $5.1 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.